Fig. 1.
RC-101 retards the growth of nasal carriage and clinical strains of S. aureus. Shown are growth curves for three representative nasal carriage strains (D20-7, D535-6, and D30) and one representative clinical strain (USA300) treated with RC-101. Delta GT represents the time difference between RC-101- and vehicle-treated samples to reach their respective GT values (onset of logarithmic growth phase). (Left) Representative growth curves for one of three assays; (right) data representative of three assays. *, P < 0.05; **, P < 0.01; ***, P < 0.001; n/s, nonsignificant. P values indicate statistical significance compared to vehicle-treated samples.